Dave Denton, Pfizer $PFE's chief financial officer, is departing the pharmaceutical company for a position in consumer goods, with his last day set for Aug. 15, Pfizer announced Thursday.
Stepping into the role on Aug. 16 will be Cecile Guegan, who currently holds the title of senior vice president of finance for Pfizer's global biopharmaceutical business and will serve as interim CFO while the company runs a search — both internal and external — for a permanent hire. Pfizer said the two executives will collaborate during the handover period.
In a statement, Pfizer Chairman and CEO Albert Bourla credited Denton with guiding the company through major acquisitions, including the buyouts of cancer therapy company Seagen $SGEN, migraine drugmaker Biohaven, and obesity drug developer Metsera. "Dave has been a steady and trusted steward of Pfizer's financial health, and we are grateful for his leadership," Bourla said.
Denton notified Pfizer of his decision on June 16, according to an SEC filing. The filing stated that his departure is not related to the company's financial or operating results or to any disagreements over financial, operational, accounting, or reporting policies.
Guegan joined Pfizer in 2005 and has held her current role since 2022, the company said. She previously served as vice president of finance for research and development and the business office from 2020 to 2022, and played a role in integrating Seagen into Pfizer in 2024. She holds a master's degree from Brest Business School.
Pfizer stock was down 1.6% in premarket trading Thursday.
Denton has been a prominent voice on Pfizer's financial performance. When Pfizer reported first-quarter 2026 revenue of $14.45 billion, a 5% year-over-year gain driven by growth in oncology and other recently launched and acquired products, Denton pointed to 22% year-over-year operational revenue growth from launched and acquired products as a particular highlight. The company left its full-year 2026 revenue guidance unchanged at $59.5 billion to $62.5 billion.